To understand the complex network of PD-L1 and CD155 signaling in tumor immunity, further studies will be needed to explore the dynamics of the association of CD155 with PD-L1, which will possibly contribute to the development of novel immunotherapies for the treatment of several cancer types. This evidence concerns the gene PVR and neoplasm.